Aurora Cannabis (ACB) Non-Current Debt (2019 - 2026)
Aurora Cannabis (ACB) posted quarterly Non-Current Debt of $363144.4 for Q1 2026, down 98.92% year-on-year from $33.5 million in Q1 2025, and down 97.46% on a QoQ basis from $14.3 million in Q4 2025.
Aurora Cannabis (ACB) Non-Current Debt (2019 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Non-Current Debt for 8 consecutive years, with $363144.4 the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Debt fell 98.92% year-over-year to $363144.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $363144.4 (down 98.92% YoY) and the FY2026 annual result came in at $360357.6, down 98.96% from the prior year.
- Non-Current Debt retreated to $363144.4 in Q1 2026 per ACB's latest filing, from $14.3 million in the prior quarter.
- Over the last five years, Non-Current Debt for ACB reached as high as $156.4 million in Q2 2023 and fell as low as $96316.0 in Q1 2022.
- A 5-year average of $53.1 million and a median of $35.5 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2023 — Non-Current Debt jumped 155667.78% — and 2026, when it tumbled 98.92%.
- Year by year, Non-Current Debt stood at $36.8 million in 2022, then surged by 180.7% to $103.3 million in 2023, then decreased by 2.28% to $101.0 million in 2024, then plunged by 85.85% to $14.3 million in 2025, then plunged by 97.46% to $363144.4 in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $363144.4, $14.3 million, and $14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn | 363,144.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 363,144.43 |
| Dec 31, 2025 | 14.29 Mn |
| Sep 30, 2025 | 14.26 Mn |
| Jun 30, 2025 | 35.52 Mn |
| Mar 31, 2025 | 33.52 Mn |
| Dec 31, 2024 | 100.98 Mn |
| Sep 30, 2024 | 100.97 Mn |
| Jun 30, 2024 | 102.10 Mn |
| Mar 31, 2024 | 3.63 Mn |
| Dec 31, 2023 | 103.34 Mn |
| Sep 30, 2023 | 127.01 Mn |
| Jun 30, 2023 | 156.38 Mn |
| Mar 31, 2023 | 35.54 Mn |
| Dec 31, 2022 | 36.82 Mn |
| Sep 30, 2022 | 37.38 Mn |
| Jun 30, 2022 | 100,395.60 |
| Mar 31, 2022 | 96,316.00 |
| Dec 31, 2021 | 94,406.99 |
| Sep 30, 2021 | 89,768.25 |
| Jun 30, 2021 | 84,606.82 |